Elevated IL-1β and serum IL-6 expression levels in patients with COPD can activate the IL-1β-system inflammatory axis pathway and pose an increased risk for COPD frequent exacerbators (27, 28). This evidence concerns the gene IL1B and chronic obstructive pulmonary disease.